Magellan Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -100.00%
- Profit Growth 89.32%
- Ebitda 98.52%
- Net Worth -0.40%
- Total Assets -18.49%
About Magellan Life Sciences
Magellan Life Sciences Private Limited (MLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 October 2013 and has a history of 11 years and three months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nageswararao Dukkipati, Laxmi Wagle, and Abhiram Dukkipati serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100TG2013PTC090647
-
Company No.
090647
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Oct 2013
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Magellan Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhiram Dukkipati
|
Director | 22-Oct-2013 | Current |
|
Nageswararao Dukkipati
|
Director | 22-Oct-2013 | Current |
|
Laxmi Wagle
|
Director | 08-Jan-2018 | Current |
Financial Performance of Magellan Life Sciences.
Magellan Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial improvement in profitability, with a 89.32% increase in profit. The company's net worth dipped by a decrease of 0.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Magellan Life Sciences?
In 2022, Magellan Life Sciences had a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Jayem Automotives Private LimitedNageswararao Dukkipati is a mutual person
-
X_Design Ventures LlpNageswararao Dukkipati is a mutual person
-
Drive Lozics Private Limited
Nageswararao Dukkipati and Abhiram Dukkipati are mutual person
-
Magellan Synthetic Biology Llp
Laxmi Wagle is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Magellan Life Sciences?
Unlock and access historical data on people associated with Magellan Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Magellan Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Magellan Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.